Skip to main content
Erschienen in: American Journal of Clinical Dermatology 2/2008

01.04.2008 | Original Research Article

Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only

Results of the 2005 Spring US National Psoriasis Foundation Survey

verfasst von: David H. Ciocon, Elizabeth J. Horn, Dr Alexa B. Kimball

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction: Five to forty percent of patients with cutaneous psoriasis develop an inflammatory, oligoarticular spondyloarthropathy known as psoriatic arthritis.
Objective: To compare health-related quality of life (QOL) between cutaneous psoriatic patients with and without psoriatic arthritis.
Method: Secondary cross-sectional analysis of data obtained from the 2005 Spring US National Psoriasis Foundation Quality of Life Telephone/Internet Survey. 426 patients with psoriasis and/or psoriatic arthritis were included in the 2005 survey. Among these respondents, the self-reported disease histories of 140 patients with cutaneous psoriasis and psoriatic arthritis were compared with those of 278 patients with cutaneous psoriasis only. Both groups were compared with respect to demographics, skin disease severity, treatment history and satisfaction, and QOL using previously validated assessment scales.
Results: Compared with those with skin psoriasis only, respondents with cutaneous psoriasis and psoriatic arthritis were slightly older, more likely to be female and members of the National Psoriasis Foundation, and more likely to report a younger age of disease onset. They were also more likely to be unemployed, to report their job was affected by their condition, and to report a higher mean estimate of lost annual wages. On both univariate and multivariate analysis, however, no significant differences between groups were detected in skin disease severity, overall QOL, and satisfaction with current treatment options. At the same time, individuals with skin psoriasis and psoriatic arthritis were more likely to be taking systemic agents. They also reported higher mean scores for pain, while those with cutaneous psoriasis reported higher mean scores for self-consciousness only.
Conclusion: In contrast to previous reports that did not control for skin disease severity, this study demonstrates that patients with cutaneous psoriasis and psoriatic arthritis do not report significantly worse health-related QOL compared with patients with cutaneous psoriasis only. Nor do they report significantly greater dissatisfaction with current treatment options. These findings may reflect the intrinsic inadequacy of the QOL instruments used in this study for capturing the additional burden of joint disease. Alternatively, these findings may reflect the existence of a threshold of joint disease in patients with skin psoriasis and psoriatic arthritis below which joint symptoms are perceived as negligible relative to cutaneous disease.
Literatur
1.
Zurück zum Zitat Mease PJ, Menter AM. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2005 54: 685–704CrossRef Mease PJ, Menter AM. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2005 54: 685–704CrossRef
2.
Zurück zum Zitat Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 49 Suppl.: S57–61CrossRef Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 49 Suppl.: S57–61CrossRef
3.
Zurück zum Zitat Weiss SC, Kimball AB, Liewehr DJ. Quantifying the harmful effects of psoriasis on health-related quality of life. J Am Acad Dermatol 2002 47: 512–8PubMedCrossRef Weiss SC, Kimball AB, Liewehr DJ. Quantifying the harmful effects of psoriasis on health-related quality of life. J Am Acad Dermatol 2002 47: 512–8PubMedCrossRef
4.
Zurück zum Zitat Husted JA, Gladman DD, Farewell VT. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001 45: 151–8PubMedCrossRef Husted JA, Gladman DD, Farewell VT. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001 45: 151–8PubMedCrossRef
5.
Zurück zum Zitat Krueger G, Koo J, Lebwohl M. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 (3): 280–4PubMed Krueger G, Koo J, Lebwohl M. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 (3): 280–4PubMed
6.
Zurück zum Zitat Kimball AB, Jacobson C, Weiss S. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005 6 (6): 383–92PubMedCrossRef Kimball AB, Jacobson C, Weiss S. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005 6 (6): 383–92PubMedCrossRef
7.
Zurück zum Zitat Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19: 210–6PubMedCrossRef Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19: 210–6PubMedCrossRef
8.
Zurück zum Zitat Gladman DD, Helliwell P, Mease PJ. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004 50 (1): 24–35PubMedCrossRef Gladman DD, Helliwell P, Mease PJ. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004 50 (1): 24–35PubMedCrossRef
9.
Zurück zum Zitat O’Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996 313: 919–21PubMedCrossRef O’Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996 313: 919–21PubMedCrossRef
10.
Zurück zum Zitat Kay L, Myers A, Walker D. Effects of inflammatory arthritis on quality of life in patients with psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1655PubMedCrossRef Kay L, Myers A, Walker D. Effects of inflammatory arthritis on quality of life in patients with psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1655PubMedCrossRef
11.
Zurück zum Zitat Lundberg L, Johannesson M, Silverdahl M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000 80 (6): 430–4PubMedCrossRef Lundberg L, Johannesson M, Silverdahl M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000 80 (6): 430–4PubMedCrossRef
12.
Zurück zum Zitat Zachariae H, Zachariae R, Blomqvist K. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002 82 (2): 108–13PubMedCrossRef Zachariae H, Zachariae R, Blomqvist K. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002 82 (2): 108–13PubMedCrossRef
13.
Zurück zum Zitat Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002 3: 171–9CrossRef Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002 3: 171–9CrossRef
14.
Zurück zum Zitat Koo J, Kozma CM, Menter A. Development of the 12 item Psoriasis Quality of Life Questionnaire (PQOL) [poster no. 606]. 61st annual meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco (CA) Koo J, Kozma CM, Menter A. Development of the 12 item Psoriasis Quality of Life Questionnaire (PQOL) [poster no. 606]. 61st annual meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco (CA)
15.
Zurück zum Zitat Krueger GG, Feldman SR, Camisa C. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281–5PubMedCrossRef Krueger GG, Feldman SR, Camisa C. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281–5PubMedCrossRef
16.
Zurück zum Zitat Nijsten T, Rolstad T, Feldman SR. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005 141 (1): 19–26PubMedCrossRef Nijsten T, Rolstad T, Feldman SR. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005 141 (1): 19–26PubMedCrossRef
17.
Zurück zum Zitat Symmons DP, Lunt M, Watkins G. Developing classification criteria for peripheral joint psoriatic arthritis: step I. Establishing whether the rheumatologist’s opinion on the diagnosis can be used as the “gold standard” J Rheumatol 2006 33 (3): 552–7 Symmons DP, Lunt M, Watkins G. Developing classification criteria for peripheral joint psoriatic arthritis: step I. Establishing whether the rheumatologist’s opinion on the diagnosis can be used as the “gold standard” J Rheumatol 2006 33 (3): 552–7
18.
Zurück zum Zitat Stamm TA, Nell V, Mathis M. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007 57 (3): 487–94PubMedCrossRef Stamm TA, Nell V, Mathis M. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007 57 (3): 487–94PubMedCrossRef
Metadaten
Titel
Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only
Results of the 2005 Spring US National Psoriasis Foundation Survey
verfasst von
David H. Ciocon
Elizabeth J. Horn
Dr Alexa B. Kimball
Publikationsdatum
01.04.2008
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2008
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200809020-00004

Weitere Artikel der Ausgabe 2/2008

American Journal of Clinical Dermatology 2/2008 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.